GLP-1 Climate Risks: A Metabolic Carbon Liberation Hypothesis

The rapid clinical adoption of glucagon-like peptide-1 (GLP-1) receptor agonists and related anti-obesity pharmacotherapies represents one of the most consequential therapeutic shifts in metabolic medicine in decades. Large-scale trials of semaglutide and tirzepatide have demonstrated sustained weight reductions approaching 15–22% of baseline body weight in adults with overweight and obesity [1][2][3]. At the same time, an estimated 40% of the global adult population is classified as overweight or obese (body mass index ≥25 kg/m²), representing roughly 3 billion individuals worldwide [4].

In parallel with these clinical advances, climate science continues to refine the quantification of carbon fluxes across atmospheric, oceanic, terrestrial, and anthropogenic reservoirs [5]. An overlooked carbon pool, however, sits in plain sight: excess human adipose tissue and widespread, synchronised pharmacological weight loss could generate a measurable pulse of carbon dioxide (CO₂) into the atmosphere via accelerated metabolic oxidation of stored lipid.

Human Adipose Tissue as an Anthropogenic Carbon Sink

Adipose tissue functions primarily as an energy reservoir, storing triglycerides for later mobilisation. From a biochemical perspective, triglycerides are carbon-rich molecules composed of glycerol esterified to three fatty acids. Lipids are approximately 77% carbon by molecular weight [6]. In individuals with overweight or obesity, excess adipose mass frequently exceeds 15–25 kg compared with healthy-weight counterparts [7].

Using conservative midpoint assumptions, a conceptual global adipose carbon model can be constructed:

• 3 billion overweight adults × 20 kg excess adipose = 60 × 10⁹ kg adipose (60 Mt).
• Carbon fraction ≈ 0.77 → 46 × 10⁹ kg carbon (46 Mt C).
• Oxidation to CO₂ (molecular ratio 44/12 ≈ 3.67) → ~169 Mt CO₂.

Thus, excess adiposity may represent approximately 169 million tonnes of potential CO₂ stored in human biomass. In comparison, annual global fossil CO₂ emissions exceed 40 gigatonnes (Gt) [5]. While 169 Mt CO₂ constitutes only ~0.4% of annual emissions, it is not trivial when compared to the annual emissions of some mid-sized industrialised nations [8].

Importantly, adipose carbon resides within the short carbon cycle. It originates from food crops that fixed atmospheric CO₂ via photosynthesis and is destined, eventually, to return to the atmosphere through respiration. The novelty in this framing lies not in the existence of this carbon flux, but in the possibility of its coordinated acceleration.

Pharmacologically Mediated Carbon Liberation

GLP-1 receptor agonists exert their therapeutic effect primarily through appetite suppression, delayed gastric emptying, and enhanced satiety [1][2][9]. Sustained caloric deficit leads to adipocyte lipolysis, releasing fatty acids into circulation. These undergo β-oxidation within mitochondria, generating acetyl-CoA, which enters the tricarboxylic acid cycle, culminating in oxidative phosphorylation. The terminal carbon product of this metabolic cascade is CO₂, exhaled via the lungs [10].

If global access to effective anti-obesity pharmacotherapy expanded dramatically over the next 2 years, a plausible scenario given manufacturing scale-up and policy prioritisation, a synchronised reduction in adipose mass could occur across hundreds of millions to billions of individuals. Assuming an average 15–20% body weight reduction, and that the majority of excess adipose carbon is oxidised within 12–18 months, the theoretical CO₂ liberation would likely be distributed over a relatively short temporal window.

Modelling a scenario in which approximately 100–150 Mt CO₂ is released over 12 months suggests a transient “anthropometabolic emissions pulse.” Relative to fossil carbon emissions, this increment is small; however, its conceptual significance lies in the coordination and intentionality of the underlying driver: pharmacological human biomass decarbonisation.

Behavioural Amplification: The Metabolic Rebound Effect

Weight loss frequently correlates with increased mobility, improved exercise tolerance, and greater engagement in physical activity [11]. Elevated activity increases minute ventilation and metabolic turnover, thereby increasing CO₂ production per unit time relative to a sedentary state. Although such emissions are part of normal physiological flux, a population-wide behavioural shift toward increased activity could marginally elevate aggregate respiratory carbon output.

More subtly, increased energy expenditure often stimulates appetite, raising caloric demand. Food production systems account for a significant share of anthropogenic greenhouse gas emissions, including CO₂, methane (CH₄), and nitrous oxide (N₂O) [12]. If sustained pharmacologically mediated weight loss were accompanied by increased caloric throughput, even at stable body mass, agricultural output could expand modestly, amplifying emissions through fertiliser use, livestock enteric fermentation, and supply chain logistics.

Furthermore, expanded participation in recreational activity may stimulate ancillary carbon-intensive industries: athletic apparel production, gym construction, sports travel, and dietary supplementation. Though diffuse and modest individually, these secondary effects illustrate a playful “metabolic rebound effect,” wherein human health gains cascade into systemic metabolic and economic fluxes.

Translating Emissions to Climate Metrics

To contextualise the magnitude of 169 Mt CO₂, it is helpful to situate the estimate within established carbon-climate sensitivity relationships. Current models suggest that cumulative emissions of ~1,000 Gt CO₂ are associated with approximately 0.45°C of global mean temperature increase over long-term equilibrium [13].

An incremental 0.17 Gt CO₂ thus represents ~0.017% of that threshold. Even under linear scaling (an oversimplification), the implied temperature increase would be on the order of 0.00008°C. Applying a canonical long-term sea-level sensitivity of ~0.3 metres per °C of warming [14], the corresponding equilibrium sea-level rise would approximate 0.024 millimetres — roughly the thickness of a human hair.

Such calculations underscore the reassuring conclusion that pharmacologically induced adipose decarbonisation would have a negligible impact on planetary systems relative to fossil fuel combustion. Yet they also serve as a reminder that carbon accounting operates across scales ranging from mitochondria to megatonnes.

Integrating Human Biomass into Earth System Thinking

Earth system models traditionally account for carbon stored in forests, soils, oceans, and industrial infrastructure. Human biomass is typically treated implicitly within the biosphere. However, global nutritional transitions, including rising obesity prevalence, have altered aggregate human body mass distributions. One speculative analysis has previously estimated that increases in average human body mass modestly increase global food energy demand and associated emissions [15].

The reverse scenario, coordinated reduction in average body mass, could therefore be conceptualised as a temporary contraction of a distributed carbon reservoir. While trivial in magnitude relative to fossil reserves, the framing highlights a rarely articulated intersection between public health interventions and biogeochemical cycles.

This thought experiment invites a broader reflection on carbon narratives. Fossil carbon represents carbon sequestered over geological timescales and rapidly liberated into the atmosphere. Adipose carbon, by contrast, circulates over timescales of months to years. The former drives long-term climate change; the latter participates in dynamic equilibrium. Confusing these categories would be scientifically erroneous, yet juxtaposing them reveals the elegance of metabolic integration within planetary systems.

Limitations and Perspective

Several caveats temper this analysis. First, adipose carbon originates from atmospheric CO₂ fixed by plants; its eventual return through respiration does not add new carbon to the long-term atmospheric reservoir. Second, our estimates assume homogeneous weight loss across heterogeneous populations and do not account for compensatory dietary intake patterns. Third, the secondary behavioural and economic feedbacks described are speculative and likely minor compared with structural drivers of emissions.

Most importantly, the climate benefits of reduced morbidity, improved mobility, and increased life expectancy associated with effective obesity treatment vastly outweigh any theoretical carbon perturbation described here. A 2025 estimate also suggested that heart failure patients saved about 0.25 kilograms of CO₂ emissions per person annually when taking GLP-1 drugs, because they were less likely to require hospitalisation. The authors suggested that when this figure is scaled up to the millions of patients eligible for these therapies, it adds up to over 2 billion kg CO₂-equivalent saved (roughly equal to 20,000 full-capacity Boeing 747 long-haul flights) [16]. Interestingly, The New York Times recently spotlighted an intriguing side effect of the GLP-1 weight-loss drug boom: lighter airplanes (January 19, 2026). the Times cited a report that if adults continue adopting drugs like Ozempic and Wegovy, the average passenger weight could drop significantly.

On the other hand, GLP-1s are among the most environmentally costly drugs. Their manufacturing, packaging, delivery, and disposal leave a heavy footprint that healthcare systems cannot afford to ignore if they are serious about net-zero commitments [17][18].

Conclusion

The present commentary is intended not as policy guidance but as an interdisciplinary reflection.

The global expansion of GLP-1 receptor agonists and related anti-obesity therapies represents a triumph of translational metabolic science. In reimagining excess adipose tissue as a distributed anthropogenic carbon sink, we have explored, with quantitative seriousness and seasonal levity, the possibility that rapid, synchronised weight loss could generate a transient CO₂ pulse measurable in megatonnes yet negligible in climatic consequence.

Ultimately, this exercise illustrates the interconnectedness of physiology and planetary systems: every exhaled breath links mitochondrial oxidation to atmospheric chemistry. Fortunately for coastal cities, the liberation of humanity’s excess triglycerides is unlikely to trouble the tide gauges, it may be a useful reminder that, once again, those with access to these therapies are unlikely to be the ones to suffer most from climate change.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in adults with type 2 diabetes (SURPASS-2). Lancet. 2021;398(10311):1487–1499.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of weekly subcutaneous semaglutide vs placebo on weight loss in adults with overweight (STEP 1). JAMA. 2021;325(14):1403–1413.
4. Ng M, Fleming T, Robinson M, et al. Global prevalence of overweight and obesity. Lancet. 2014;384(9945):766–781.
5. Friedlingstein P, O’Sullivan M, Jones MW, et al. Global Carbon Budget 2023. Earth Syst Sci Data. 2023;15:343–533.
6. Lepage G, Roy CC. Direct transesterification of lipids. J Lipid Res. 1986;27(1):114–120.
7. Wells JC. Body composition and adiposity estimation accuracy. Eur J Clin Nutr. 2019;73(3):330–339.
8. Le Quéré C, Andrew RM, Friedlingstein P, et al. Global Carbon Budget 2018. Earth Syst Sci Data. 2018;10:2141–2194.
9. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of once-weekly semaglutide. Lancet Diabetes Endocrinol. 2015;3(9):706–714.
10. McArdle WD, Katch FI, Katch VL. Exercise Physiology. 8th ed. Philadelphia: Wolters Kluwer; 2015.
11. Jakicic JM, Marcus BH, Lang W, et al. Effect of exercise on weight loss maintenance. Arch Intern Med. 2008;168(14):1550–1559.
12. Gerber PJ, Steinfeld H, Henderson B, et al. Tackling climate change through livestock. FAO; 2013.
13. Pierrehumbert RT. The two-state problem in climate overshoot and long-term carbon stability. Proc Nat Acad of Sci. 2014;111(9):3343–3348.
14. Church JA, White NJ. Sea-level rise from the late 19th to early 21st century. Surv Geophys. 2011;32:585–602.
15. Walpole SC, Prieto-Merino D, Edwards P, et al. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012;12:439.
16. Makwana B, et al. Environmental impact of novel anti-obesity medications on healthcare-related greenhouse gas emissions in patients with heart failure with preserved ejection fraction. ESC Congress 2025, abstract 86569.
17. Tonks O. (2025). GLP-1s and the Environment: The Silent Cost of a Medical Revolution
18. Lawson E. (2025). How Heavy Is the Footprint? Comparing Wegovy’s Carbon Impact to Other Medications.